PARP inhibitors Genetron Health, Impact Therapeutics Partner for Anti-Cancer Drug, CDx Development The companies will cooperate in drug target discovery and, potentially, companion diagnostic development for novel synthetic lethal inhibitors. Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib. Prostate Cancer Genomics Study IDs PARP Inhibitors as Potentially Beneficial to Black Men Some genes were more frequently mutated in prostate cancers from Black men, but the researchers said that social inequities also lead to poorer health outcomes. Personalis to Provide Immunogenomic Profiling for University of New Mexico Ovarian Cancer Study The company will test samples from women treated with an investigational combination of AstraZeneca's PARP inhibitor olaparib and immunotherapy tremelimumab. Harvard Team Advancing Algorithmic Signature to Improve PARP Inhibitor Patient Selection Premium The group published results showing its method can faithfully recapitulate genome-wide measures of DNA repair deficiency using much smaller sequencing panels. Dec 19, 2018 FDA Approves Myriad Genetics' BRACAnalysis CDx With Lynparza in Earlier Ovarian Cancer Setting Oct 16, 2018 FDA Approves Myriad Genetics BRCA CDx With Pfizer's Metastatic Breast Cancer Drug Oct 10, 2018 Myriad Upgraded to Overweight by Piper Jaffray; Signs Lab Service Deal with Pfizer Sep 28, 2018 BRCA1 Methylation Level May Predict Which Ovarian Cancer Patients Respond to PARP Inhibitors Jul 16, 2018 PARP Inhibitors May Benefit Patients With Rare Hereditary Cancer Syndromes May 31, 2018 PanDrugs System Aims to Advance Precision Cancer Care by Matching Treatments to Mutations Premium May 11, 2018 PARP Inhibitor Resistance Gene Identified Using CRISPR Screen Dec 8, 2017 Pfizer PARP Inhibitor Delays Progression Over Chemotherapy in BRCA-Mutated Advanced Breast Cancer Premium Jul 11, 2017 After Securing CE-IVD for Debut Hereditary Cancer Dx, Korea's NGeneBio Readies NGS Tests for Launch Premium Mar 27, 2017 FDA Approves Myriad Genetics' BRACAnalysis as Complementary Dx for New PARP Inhibitor Feb 1, 2017 Clovis, Strata Partner to Identify Prostate Cancer Best Responders to PARP Inhibitor Dec 20, 2016 Foundation Medicine's Regulatory Win for NGS CDx Sets Precedent; Adoption Challenge Remains Premium Dec 19, 2016 Foundation BRCA CDx is First NGS Companion Test to Get FDA Nod Nov 2, 2016 Myriad Moving Ahead With PMA Filing for MyChoice HRD as Companion Test for Niraparib Premium Jul 6, 2016 Ovarian Cancer Study Provides Support for Myriad's HRD Test as CDx for Tesaro's Niraparib Premium Jun 6, 2016 AstraZeneca Outlines Precision Medicine Strategy for DNA Damage Response Portfolio Premium Mar 1, 2016 Multiplicom Receives CE-IVD Mark for Ovarian Cancer CDx Test Feb 23, 2016 AbbVie to Use Myriad CDx to Support PARP Inhibitor Development Jan 18, 2016 Tumor Cell, Mouse Studies Suggest c-Met Expression as Predictor of PARP Inhibitor Resistance Oct 30, 2015 Mutational Signature Points to Possibility of Targeted Treatment for Some Stomach Cancers Load More Breaking News UK Biobank Study Investigates Incomplete Penetrance of Mendelian Disease Variants MDxHealth Q3 Revenues Grow 23 Percent BioMérieux Q3 Revenues Increase 11 Percent, Firm Raises 2021 Guidance Germline Cancer Risk Genes May Hold Rhabdomyosarcoma Survival Clues, Study Suggests Danaher Q3 Revenues Rise 23 Percent, Beat Wall Street Estimates Horse Genetics Study Reveals Origins of Domestication, Use in Human Culture The Scan Guidelines for Ancient DNA Work More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature. And Cleared A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times. Suit Over Allegations The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director. Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.